Yahoo Finance Insiders At IDEXX Laboratories Sold US$3.2m In Stock, Alluding To Potential Weakness
Many IDEXX Laboratories, Inc. (NASDAQ:IDXX) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
Check out our latest analysis for IDEXX Laboratories
IDEXX Laboratories Insider Transactions Over The Last Year
In the last twelve months, the biggest single sale by an insider was when the insider, James Polewaczyk, sold US$3.1m worth of shares at a price of US$511 per share. So what is clear is that an insider saw fit to sell at around the current price of US$467. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
Insiders in IDEXX Laboratories didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
I will like IDEXX Laboratories better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
Insiders At IDEXX Laboratories Have Sold Stock Recently
The last three months saw significant insider selling at IDEXX Laboratories. Specifically, Independent Director Bruce Claflin ditched US$108k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.
Insider Ownership Of IDEXX Laboratories
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that IDEXX Laboratories insiders own 0.9% of the company, worth about US$367m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Do The IDEXX Laboratories Insider Transactions Indicate?
An insider sold IDEXX Laboratories shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. On the plus side, IDEXX Laboratories makes money, and is growing profits. It is good to see high insider ownership, but the insider selling leaves us cautious. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for IDEXX Laboratories.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
